{"pmid":32405087,"pmcid":"PMC7218667","title":"Continue ACE inhibitors/ ARB'S till further evidence in Coronavirus disease 2019 (COVID-19).","text":["Continue ACE inhibitors/ ARB'S till further evidence in Coronavirus disease 2019 (COVID-19).","Indian Heart J","Bansal, Sandeep","Agstam, Sourabh","Gupta, Anunay","Gupta, Preeti","Isser, H S","32405087"],"journal":"Indian Heart J","authors":["Bansal, Sandeep","Agstam, Sourabh","Gupta, Anunay","Gupta, Preeti","Isser, H S"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405087","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.ihj.2020.04.007","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666802845338304512,"score":9.490897,"similar":[{"pmid":32320478,"title":"Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence.","text":["Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence.","Concerns have been raised regarding the safety of Angiotensin Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in patients with COVID-19, based on the hypothesis that such medications may raise expression of ACE2, the receptor for SARS-CoV-2. We conducted a literature review of studies (n=12) in experimental animals and human subjects (n=12) and evaluated the evidence regarding the impact of administration of ACEIs and ARBs on ACE2 expression. We prioritized studies that assessed ACE2 protein expression data, measured directly or inferred from ACE2 activity assays. The findings in animals are inconsistent with respect to an increase in ACE2 expression in response to treatment with ACEIs or ARBs. Control/sham animals show little to no effect in the plurality of studies. Those studies that report increases in ACE2 expression tend to involve acute injury models and/or higher doses of ACEIs or ARBS than are typically administered to patients. Data from human studies overwhelmingly imply that administration of ACEIs/ARBs does not increase ACE2 expression. Available evidence, in particular, data from human studies, does not support the hypothesis that ACEI/ARB use increases ACE2 expression and the risk of complications from COVID-19. We conclude that patients being treated with ACEIs and ARBs should continue their use for approved indications.","Clin Pharmacol Ther","Sriram, Krishna","Insel, Paul A","32320478"],"abstract":["Concerns have been raised regarding the safety of Angiotensin Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in patients with COVID-19, based on the hypothesis that such medications may raise expression of ACE2, the receptor for SARS-CoV-2. We conducted a literature review of studies (n=12) in experimental animals and human subjects (n=12) and evaluated the evidence regarding the impact of administration of ACEIs and ARBs on ACE2 expression. We prioritized studies that assessed ACE2 protein expression data, measured directly or inferred from ACE2 activity assays. The findings in animals are inconsistent with respect to an increase in ACE2 expression in response to treatment with ACEIs or ARBs. Control/sham animals show little to no effect in the plurality of studies. Those studies that report increases in ACE2 expression tend to involve acute injury models and/or higher doses of ACEIs or ARBS than are typically administered to patients. Data from human studies overwhelmingly imply that administration of ACEIs/ARBs does not increase ACE2 expression. Available evidence, in particular, data from human studies, does not support the hypothesis that ACEI/ARB use increases ACE2 expression and the risk of complications from COVID-19. We conclude that patients being treated with ACEIs and ARBs should continue their use for approved indications."],"journal":"Clin Pharmacol Ther","authors":["Sriram, Krishna","Insel, Paul A"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320478","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/cpt.1863","keywords":["ace inhibitors","ace2","angiotensin ii","angiotensin receptor blockers","covid-19"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493723607040,"score":77.41156},{"pmid":32292227,"pmcid":"PMC7151242","title":"[Controversy regarding ACE inhibitors / ARBs in Covid-19].","text":["[Controversy regarding ACE inhibitors / ARBs in Covid-19].","Rev Esp Cardiol","Soria Arcos, Federico","Romero-Puche, Antonio","Vicente Vera, Tomas","32292227"],"journal":"Rev Esp Cardiol","authors":["Soria Arcos, Federico","Romero-Puche, Antonio","Vicente Vera, Tomas"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292227","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.recesp.2020.03.014","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494495358977,"score":77.31805},{"pmid":32371022,"title":"Controversy regarding ACE inhibitors / ARBs in COVID-19.","text":["Controversy regarding ACE inhibitors / ARBs in COVID-19.","Rev Esp Cardiol (Engl Ed)","Soria Arcos, Federico","Romero Puche, Antonio","Vicente Vera, Tomas","32371022"],"journal":"Rev Esp Cardiol (Engl Ed)","authors":["Soria Arcos, Federico","Romero Puche, Antonio","Vicente Vera, Tomas"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32371022","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.rec.2020.04.004","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496440467456,"score":77.31805},{"pmid":32427636,"title":"ACE Inhibitors and ARBs in Patients with COVID-19: Friend or Foe?","text":["ACE Inhibitors and ARBs in Patients with COVID-19: Friend or Foe?","Cardiol Rev","Shyh, Grace I","Nawarskas, James J","Cheng-Lai, Angela","32427636"],"journal":"Cardiol Rev","authors":["Shyh, Grace I","Nawarskas, James J","Cheng-Lai, Angela"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32427636","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1097/CRD.0000000000000319","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667252837748310017,"score":70.99406},{"pmid":32472989,"title":"Relationship between ACE-inhibitors, ARBs and SARS-CoV-2 infection: where are we?","text":["Relationship between ACE-inhibitors, ARBs and SARS-CoV-2 infection: where are we?","SARS-CoV-2 is spreading rapidly all over the world. The case fatality rate seems higher in cardiovascular disease and hypertension. Other comorbidities do not seem to confer the same risk, therefore the understanding of the relationship between infection and cardiovascular system could be a crucial point for the fight against the virus. A great interest is currently directed towards the angiotensin 2 converting enzyme (ACE 2) which is the SARS-CoV-2 receptor and creates important connections between the virus replication pathway, the cardiovascular system and blood pressure. All cardiovascular conditions share an imbalance of the renin angiotensin system (RAAS) in which ACE 2 plays a central role. In the last few days, much confusion has appeared about the management of therapy with angiotensin converting enzyme inhibitors (ACE-i) and angiotensin receptor blockers (ARBs) in infected patients and in those at risk of critical illness in case of infection. In this article we will try to reorder the major opinions currently emerging on this topic.","Minerva Cardioangiol","Infusino, Fabio","Cimino, Sara","Lombardi, Marco","Mancone, Massimo","Cavarretta, Elena","Frati, Giacomo","Pugliese, Francesco","Fedele, Francesco","Biondi-Zoccai, Giuseppe","32472989"],"abstract":["SARS-CoV-2 is spreading rapidly all over the world. The case fatality rate seems higher in cardiovascular disease and hypertension. Other comorbidities do not seem to confer the same risk, therefore the understanding of the relationship between infection and cardiovascular system could be a crucial point for the fight against the virus. A great interest is currently directed towards the angiotensin 2 converting enzyme (ACE 2) which is the SARS-CoV-2 receptor and creates important connections between the virus replication pathway, the cardiovascular system and blood pressure. All cardiovascular conditions share an imbalance of the renin angiotensin system (RAAS) in which ACE 2 plays a central role. In the last few days, much confusion has appeared about the management of therapy with angiotensin converting enzyme inhibitors (ACE-i) and angiotensin receptor blockers (ARBs) in infected patients and in those at risk of critical illness in case of infection. In this article we will try to reorder the major opinions currently emerging on this topic."],"journal":"Minerva Cardioangiol","authors":["Infusino, Fabio","Cimino, Sara","Lombardi, Marco","Mancone, Massimo","Cavarretta, Elena","Frati, Giacomo","Pugliese, Francesco","Fedele, Francesco","Biondi-Zoccai, Giuseppe"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472989","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.23736/S0026-4725.20.05271-8","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668255193434685440,"score":70.99406}]}